We Are Hiring A Clinical Data Manager
At EORTC, we are looking for a Clinical Data Manager to join our HQ team in Brussels.
At EORTC, we are looking for a Clinical Data Manager to join our HQ team in Brussels.
Cancer stemness, regarded as a crucial factor in tumor development, has been recognized to involve a plastic cellular state influenced by dynamic interactions between cancer…
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK.
Here, we summarize an analysis of CD19-targeting CAR T-cell therapy in patients with PCNSL or SCNSL, presented by Ossami Saidy during the 50th Annual Meeting…
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II SECOMBIT (NCT02631447) trial, which evaluated the best…
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.